EcoDrugPlus

60s Ribosomal Protein L29-Like

Ensembl ID : ENSCJAG00000084224
Gene Symbol: LOC108593639
4 Cross references
250 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

60s Ribosomal Protein L29-Like

Ensembl ID : ENSCJAG00000079055
Gene Symbol: LOC118153857
4 Cross references
250 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

60s Ribosomal Protein L29-Like

Ensembl ID : ENSCJAG00000085256
Gene Symbol: LOC118149151
4 Cross references
250 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

60s Ribosomal Protein L29-Like

Ensembl ID : ENSCJAG00000085859
Gene Symbol: LOC108593607
4 Cross references
250 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

60s Ribosomal Protein L29-Like

Ensembl ID : ENSCJAG00000078183
Gene Symbol: LOC108593389
4 Cross references
250 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

60s Ribosomal Protein L29-Like

Ensembl ID : ENSCJAG00000082814
Gene Symbol: LOC108589603
4 Cross references
250 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

60s Ribosomal Protein L38-Like

Ensembl ID : ENSCJAG00000021822
Gene Symbol: LOC100388363
4 Cross references
215 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

60s Ribosomal Protein L6-Like

Ensembl ID : ENSCJAG00000084186
Gene Symbol: LOC100389591
4 Cross references
291 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

A-Raf Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSCJAG00000012431
Gene Symbol: ARAF
5 Cross references
192 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Abl Proto-Oncogene 1, Non-Receptor Tyrosine Kinase

Ensembl ID : ENSCJAG00000020525
Gene Symbol: ABL1
5 Cross references
204 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Adam Metallopeptidase Domain 17

Ensembl ID : ENSCJAG00000006369
Gene Symbol: ADAM17
5 Cross references
283 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Adam Metallopeptidase With Thrombospondin Type 1 Motif 5

Ensembl ID : ENSCJAG00000013997
Gene Symbol: ADAMTS5
5 Cross references
199 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).